Can you introduce Diatheva and its position within SOL Group?

Diatheva was founded in 2002 as a spin-off of the University of Urbino, in Italy, and in 2012 it was acquired by SOL group. Diatheva is part of the Biotechnology Division of SOL Group, a global leader in medical gasses that in the last ten years started differentiating its activities and investing also in the biotech field. SOL group 2020 revenue was about €1 billion. Diatheva specializes in the field of diagnostic kits but, above all, we offer CDMO services regarding the GMP production of biopharmaceutical active ingredients. By collaborating with both private and public entities, our mission is to bring research into application. We work in synergy with the other SOL biotech companies – CryoLab and Personal Genomics.

We are well positioned to provide support at all stages of the biopharmaceutical process development, from small scale to large production. In our state-of-the art GMP production facility authorized by EMA we produce and release biological APIs for preclinical and Phase I/II clinical trials. Our R&D department and university R&D labs together speak the same language and we leverage our development and industrialization resources to turn their ideas into a successful product.

 

What are Diatheva’s current R&D projects?

One of our current most important R&D projects focuses on woman’s health and consists in the development of a new diagnostic kit for endometriosis. This is a pathology that affects 10-15% of women of reproductive age and the percentage increases to 30-50% in case of women with difficulties in conception. Its diagnosis is a long and invasive process that usually takes years. In collaboration with the inventor Prof. Signorile, who is the President of the Italian Endometriosis Foundation, Diatheva is industrializing a kit based on innovative biomarkers that can be easily identified starting from a saliva sample.

We have our own research and development of three novel biologic therapeutics in the oncology and infectious diseases areas.

 

To find out more click on the following link: https://www.gbreports.com/interview/cosimo-lenti